FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Todos Medical Announces Publication Demonstrating Potential of FTIR Platform to Identify Bacterial and Viral Infections.”
Todos Medical Ltd. (OTCQB: TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced the publication of data from a human clinical study in the scientific journal Analytical Chemistry entitled “Differential Diagnosis of the Etiologies of Bacterial and Viral Infections Using Infrared Microscopy of Peripheral Human Blood Samples and Multivariate Analysis”. The data demonstrate that the use of the Fourier-transform infrared (FTIR) spectroscopy technique on peripheral blood samples yields a differential diagnosis when seeking to make a clinical diagnosis between patients with viral infections, bacterial infections and healthy controls.
Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer’s disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Breakthrough Diagnostics is developing the LymPro Test®, a blood test for diagnosing Alzheimer’s disease.
Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, fungi and parasites, and can be transmitted by direct or indirect contact. Globally, infectious diseases such as malaria, HIV, tuberculosis, influenza, hepatitis A, hepatitis C and recently the novel (new) coronavirus (named “2019-nCoV”) put major strains on public health. However, infectious disease therapeutics are used to constrain the growth of these diseases, as these drugs can act through the host’s defense system and directly target the malicious pathogen. Overall, the growth of this market is influenced by various major factors, such as the increasing occurrence of infectious diseases, the growing use of direct-acting anti-viral, growing healthcare awareness, increasing government funding in developing countries and a growing geriatric population. In addition, the public is now more aware of symptoms associated with various diseases than ever before, aiding early diagnosis rates among individuals and providing growth opportunities for the market. And, in 2019, the Global Infectious Disease Therapeutics Market size was worth USD 105.13 Billion; it is now estimated to reach USD 154.18 Billion by the end of 2024, while a growing potential of 7.96 % during the forecast period 2019 – 2024, according to Market Data Forecast.
Among the avalanche of information concerning the recent outbreak of the 2019-nCoV, is the morsel from January 30th, 2020: The International Health Regulations Emergency Committee of the World Health Organization agreed that the outbreak now meets the criteria for a Public Health Emergency of International Concern. Representatives of the Ministry of Health of the People’s Republic of China reported on the current situation – as of late last week, there were 7,711 confirmed and 12,167 suspected cases throughout the country. Of the confirmed cases, 1370 are severe and 170 people have died. 124 people have recovered and been discharged from hospital. Meanwhile, in the United States, the CDC has announced that it is closely monitoring an outbreak of respiratory illness caused by the novel coronavirus, and that the first instance of person-to-person spread with this virus has been confirmed in the U.S on January 30th, 2020. Coronaviruses are a large family of viruses that are common in many different species of animals, including camels, cattle, cats, and bats. However, it is only rarely that animal coronaviruses can infect people and subsequently spread throughout the population, but such a list includes MERS, SARS, and now the 2019-nCoV.
For more information, please visit: Todos Medical Ltd.
For more corporate news on Todos Medical Ltd., check out the Buzz on the Street
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.